These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11927921)

  • 1. Charity's first move is drug investment.
    Mitchell P
    Nat Med; 2002 Apr; 8(4):314. PubMed ID: 11927921
    [No Abstract]   [Full Text] [Related]  

  • 2. Funding of patients' groups.
    Slevin M
    Lancet; 2006 Jul; 368(9531):202. PubMed ID: 16844488
    [No Abstract]   [Full Text] [Related]  

  • 3. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 4. J&J's billion dollar punt on anti-amyloid antibody.
    Sheridan C
    Nat Biotechnol; 2009 Aug; 27(8):679-81. PubMed ID: 19668155
    [No Abstract]   [Full Text] [Related]  

  • 5. AIDS and The Sunday Times.
    Blow D
    Nature; 1994 Jan; 367(6459):109. PubMed ID: 8114901
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 7. Ovarian carcinoma therapy with monoclonal antibodies.
    Canevari S; Miotti S; Bottero F; Valota O; Colnaghi MI
    Hybridoma; 1993 Oct; 12(5):501-7. PubMed ID: 8300122
    [No Abstract]   [Full Text] [Related]  

  • 8. Next-generation monoclonals less profitable than trailblazers?
    Mitchell P
    Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
    [No Abstract]   [Full Text] [Related]  

  • 9. Promising drug is victim of bad business.
    Dove A
    Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
    [No Abstract]   [Full Text] [Related]  

  • 10. Not so "SMART".
    Nicholson S
    J Clin Oncol; 2006 Jul; 24(21):3511-2. PubMed ID: 16849774
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer charity's rehabilitation set back.
    Balter M
    Science; 1996 Oct; 274(5286):336. PubMed ID: 8927986
    [No Abstract]   [Full Text] [Related]  

  • 12. Charity's decision to cut funding to Planned Parenthood sparks controversy.
    Roehr B
    BMJ; 2012 Feb; 344():e870. PubMed ID: 22306841
    [No Abstract]   [Full Text] [Related]  

  • 13. Can 'double blockbuster' strengthen Amgen's backbone?
    Sheridan C
    Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
    [No Abstract]   [Full Text] [Related]  

  • 14. SMART? Time will tell.
    Nat Rev Cancer; 2002 Nov; 2(11):812. PubMed ID: 12442760
    [No Abstract]   [Full Text] [Related]  

  • 15. Charity's Royal patron visits RVC's Camden hospital.
    Vet Rec; 2015 Mar; 176(10):242. PubMed ID: 25748183
    [No Abstract]   [Full Text] [Related]  

  • 16. Charities tied to doctors get drug industry gifts.
    Abelson R
    N Y Times Web; 2006 Jun; ():A1, C4. PubMed ID: 16838451
    [No Abstract]   [Full Text] [Related]  

  • 17. Staff brand changes to charity's off-duty rota system "unfair".
    Jo S
    Nurs Times; 2013 Dec 23-2014 Jan 14; 109(51):8. PubMed ID: 24592655
    [No Abstract]   [Full Text] [Related]  

  • 18. A cancer drug shows promise, at a price that many can't pay.
    Berenson A
    N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
    [No Abstract]   [Full Text] [Related]  

  • 19. Just mad about mAbs.
    Jacobs T
    Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
    [No Abstract]   [Full Text] [Related]  

  • 20. Support system: through charities, drug makers help people--and themselves.
    Anand G
    Wall St J (East Ed); 2005 Dec; ():A1, A10. PubMed ID: 16502554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.